Inventor · disambiguated record
Louise Silvestre
Also filed as: SILVESTRE LOUISE
7 granted patents·32 pending applications·26 citations·filing 2009–2024
82Inventor score
Files withSANOFI AVENTIS DEUTSCHLAND30SILVESTRE LOUISE3BOKA GABOR2NIEMOELLER ELISABETH1NIEMÖELLER ELISABETH1
Top patents by PatentIndex Score
39 records- 0184US2025177487A1Insulin glargine/lixisenatide fixed ratio formulationSANOFI AVENTIS DEUTSCHLAND·Filed 2024·Application pending·0 cites
- 0283US8735349B2Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/LSILVESTRE LOUISE·Filed 2012·Granted May 27, 2014·18 cites·9 claims
- 0382US11026999B2Insulin glargine/lixisenatide fixed ratio formulationSANOFI AVENTIS DEUTSCHLAND·Filed 2019·Granted Jun 8, 2021·1 cites·3 claims
- 0482US2025134964A1Method for inducing weight loss in a type 2 diabetes mellitus patientSANOFI AVENTIS DEUTSCHLAND·Filed 2024·Application pending·0 cites
- 0582US2025064898A1Insulin glargine/lixisenatide fixed ratio formulationSANOFI AVENTIS DEUTSCHLAND·Filed 2024·Application pending·0 cites
- 0678US12186374B2Insulin glargine/lixisenatide fixed ratio formulationSANOFI AVENTIS DEUTSCHLAND·Filed 2022·Granted Jan 7, 2025·0 cites·9 claims
- 0778US9981013B2Use of AVE0010 for the treatment of diabetes mellitus type 2SANOFI AVENTIS DEUTSCHLAND·Filed 2016·Granted May 29, 2018·2 cites·8 claims
- 0878US9950039B2Insulin glargine/lixisenatide fixed ratio formulationSANOFI AVENTIS DEUTSCHLAND·Filed 2015·Granted Apr 24, 2018·2 cites·7 claims
- 0972US2022347269A1Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulinSANOFI AVENTIS DEUTSCHLAND·Filed 2022·Application pending·0 cites
- 1071US2023028588A1Pharmaceutical combination for use in glycemic control in diabetes type 2 patientsSANOFI AVENTIS DEUTSCHLAND·Filed 2022·Application pending·0 cites
- 1171US2020338171A1Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulinSANOFI AVENTIS DEUTSCHLAND·Filed 2019·Application pending·0 cites
- 1271US2022054594A1Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2SANOFI AVENTIS DEUTSCHLAND·Filed 2021·Application pending·0 cites
- 1370US2022031811A1Insulin glargine/lixisenatide fixed ratio formulationSANOFI AVENTIS DEUTSCHLAND·Filed 2021·Application pending·0 cites
- 1469US2020353054A1Use of ave0010 for the treatment of diabetes mellitus type 2SANOFI AVENTIS DEUTSCHLAND·Filed 2019·Application pending·0 cites
- 1567US9821032B2Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulinNIEMOELLER ELISABETH·Filed 2012·Granted Nov 21, 2017·2 cites·14 claims
- 1667US2021128692A1Insulin glargine/lixisenatide fixed ratio formulationSANOFI AVENTIS DEUTSCHLAND·Filed 2020·Application pending·0 cites
- 1765US2011118178A1Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metforminSANOFI AVENTIS DEUTSCHLAND·Filed 2009·Application pending·0 cites
- 1863US2019381145A1Insulin glargine/lixisenatide fixed ratio formulationSANOFI AVENTIS DEUTSCHLAND·Filed 2019·Application pending·0 cites
- 1961US2019060411A1Insulin Glargine/Lixisenatide Fixed Ratio FormulationSANOFI AVENTIS DEUTSCHLAND·Filed 2018·Application pending·0 cites
- 2060US9408893B2Pharmaceutical combination for use in glycemic control in diabetes type 2 patientsNIEMÖELLER ELISABETH·Filed 2012·Granted Aug 9, 2016·1 cites·2 claims
- 2160US2020330559A1Pharmaceutical combination for use in glycemic control in diabetes type 2 patientsSANOFI AVENTIS DEUTSCHLAND·Filed 2020·Application pending·0 cites
- 2258US2014371141A1Insulin glargine/lixisenatide fixed ratio formulationSANOFI AVENTIS DEUTSCHLAND·Filed 2014·Application pending·0 cites
- 2358US2019030132A1Use of AVE0010 for the Treatment of Diabetes Mellitus Type 2SANOFI AVENTIS DEUTSCHLAND·Filed 2018·Application pending·0 cites
- 2457US2018339023A1Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulinSANOFI AVENTIS DEUTSCHLAND·Filed 2018·Application pending·0 cites
- 2556US2018133290A1Insulin glargine/lixisenatide fixed ratio formulationSANOFI AVENTIS DEUTSCHLAND·Filed 2017·Application pending·0 cites
- 2655US2019134160A1Pharmaceutical Combination for Use in Glycemic Control in Diabetes Type 2 PatientsSANOFI AVENTIS DEUTSCHLAND·Filed 2018·Application pending·0 cites
- 2753US2019054146A1Prevention of hypoglycemia in diabetes mellitus type 2 patientsSANOFI AVENTIS DEUTSCHLAND·Filed 2018·Application pending·0 cites
- 2851US2017143801A1Pharmaceutical Combination for Use in Glycemic Control in Diabetes Type 2 PatientsSANOFI AVENTIS DEUTSCHLAND·Filed 2017·Application pending·0 cites
- 2950US2011118180A1Method of treatment of diabetes type 2 comprising add-on therapy to metforminSANOFI AVENTIS DEUTSCHLAND·Filed 2009·Application pending·0 cites
- 3050US2011245200A1Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatmentSANOFI AVENTIS·Filed 2009·Application pending·0 cites
- 3148US2014148384A1Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2BOKA GABOR·Filed 2010·Application pending·0 cites
- 3247US2017136094A1Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metforminSANOFI AVENTIS DEUTSCHLAND·Filed 2016·Application pending·0 cites
- 3346US2017080057A1Prevention of hypoglycemia in diabetes mellitus type 2 patientsSANOFI AVENTIS DEUTSCHLAND·Filed 2016·Application pending·0 cites
- 3445US2013085102A1Prevention of hypoglycemia in diabetes mellitus type 2 patientsSILVESTRE LOUISE·Filed 2012·Application pending·0 cites
- 3543US2018000902A1Prevention of hypoglycaemia in diabetes mellitus type 2 patientsSANOFI AVENTIS DEUTSCHLAND·Filed 2017·Application pending·0 cites
- 3642US2012277147A1Prevention of hypoglycaemia in diabetes mellitus type 2 patientsBOKA GABOR·Filed 2012·Application pending·0 cites
- 3737US2013040878A1Pharmaceutical combination for use in the treatment of diabetes type 2 patientsSANOFI AVENTIS DEUTSCHLAND·Filed 2012·Application pending·0 cites
- 3836US2013065828A1Pharmaceutical combination for use in glycemic control in diabetes type 2 patientsRUUS PETER·Filed 2012·Application pending·0 cites
- 3931US2013296236A1Treatment protocol of diabetes type 2SILVESTRE LOUISE·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Louise Silvestre files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →